BRPI0511367A - uso de uma composição,composição, uso de vip e/ou de um fragmento ativo do mesmo - Google Patents
uso de uma composição,composição, uso de vip e/ou de um fragmento ativo do mesmoInfo
- Publication number
- BRPI0511367A BRPI0511367A BRPI0511367-9A BRPI0511367A BRPI0511367A BR PI0511367 A BRPI0511367 A BR PI0511367A BR PI0511367 A BRPI0511367 A BR PI0511367A BR PI0511367 A BRPI0511367 A BR PI0511367A
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- vip
- active fragment
- relates
- prophylactic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
Abstract
USO DE UMA COMPOSIçãO, COMPOSIçãO, USO DE VIP E/OU DE UM FRAGMENTO ATIVO DO MESMO". A presente invenção está relacionada com composição e métodos para tratamento de determinadas condições cardiovasculares. Em particular, ela está relacionada com o tratamento profilático ou terapêutico da fibrose miocardial ou condições associadas através da administração de composições compreendendo peptídeo intestinal vasoativo (VIP) e/ou fragmento(s) ativo(s) do mesmo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2004903188A AU2004903188A0 (en) | 2004-06-11 | Treatment of myocardial fibrosis | |
AU2004903188 | 2004-06-11 | ||
PCT/AU2005/000835 WO2005120545A1 (en) | 2004-06-11 | 2005-06-10 | Compositions and methods for treatment of cardiovascular disease |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0511367A true BRPI0511367A (pt) | 2007-12-04 |
BRPI0511367B1 BRPI0511367B1 (pt) | 2018-05-22 |
BRPI0511367B8 BRPI0511367B8 (pt) | 2021-05-25 |
Family
ID=35502830
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0511367A BRPI0511367B8 (pt) | 2004-06-11 | 2005-06-10 | uso de uma composição,composição, uso de vip e/ou de um fragmento ativo do mesmo |
Country Status (17)
Country | Link |
---|---|
US (1) | US7951777B2 (pt) |
EP (1) | EP1768689B1 (pt) |
JP (1) | JP4824682B2 (pt) |
KR (2) | KR101638308B1 (pt) |
CN (1) | CN1993137B (pt) |
AU (1) | AU2005251386B8 (pt) |
BR (1) | BRPI0511367B8 (pt) |
CA (1) | CA2573439C (pt) |
DK (1) | DK1768689T3 (pt) |
ES (1) | ES2523659T3 (pt) |
HK (1) | HK1102508A1 (pt) |
IL (1) | IL179931A (pt) |
MX (1) | MXPA06014462A (pt) |
NZ (1) | NZ552130A (pt) |
RU (1) | RU2387454C2 (pt) |
WO (1) | WO2005120545A1 (pt) |
ZA (1) | ZA200700070B (pt) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ552130A (en) * | 2004-06-11 | 2009-10-30 | Vectus Biosystems Ltd | Compositions and methods for the treatment of cardiovascular disease |
JP2008507540A (ja) | 2004-07-21 | 2008-03-13 | チューレン ユニバーシティ ヘルス サイエンス センター | Pacap化合物を用いる腎臓機能障害及び多発性骨髄腫の治療 |
BRPI0620566B8 (pt) | 2005-12-09 | 2021-05-25 | Vectus Biosystems Ltd | composição, composição para o tratamento profilático ou terapêutico de fibrose miocardial ou uma condição associada, composição para o tratamento profilático ou terapêutico de hipertensão, uso de uma composição, uso de vip ou de um fragmento do mesmo e uso de um vip |
US8841255B2 (en) * | 2005-12-20 | 2014-09-23 | Duke University | Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides |
US20130172274A1 (en) | 2005-12-20 | 2013-07-04 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
US8334257B2 (en) | 2005-12-20 | 2012-12-18 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
US20100204116A1 (en) * | 2007-09-11 | 2010-08-12 | Dorian Bevec | Use of calcitonin as anti-angiogenic agent |
EP3412300A1 (en) | 2008-06-27 | 2018-12-12 | Duke University | Therapeutic agents comprising elastin-like peptides |
US20110268789A1 (en) * | 2008-09-25 | 2011-11-03 | Min Li | Use of pituitary adenylate cyclase-activating polypeptide (pacap) and pacap analogs as adjunctive treatments with anticancer agents |
ES2603963T3 (es) * | 2008-10-17 | 2017-03-02 | Vectus Biosystems Limited | Composiciones y métodos para el tratamiento de trastornos renales |
US20110288001A1 (en) * | 2008-12-18 | 2011-11-24 | Homayoun Sadeghi | Biologically active proteins activatable by peptidase |
MY180681A (en) * | 2009-04-02 | 2020-12-06 | Vectus Biosystems Pty Ltd | Compositions and methods for treatment of aortic fibrosis |
BR112012003327A2 (pt) * | 2009-08-14 | 2017-06-06 | Phasebio Pharmaceuticals Inc | peptídeos intestinais vasoativos modificados |
WO2011054001A2 (en) | 2009-11-02 | 2011-05-05 | The Administrators Of The Tulane | Analogs of pitutary adenylate cyclase-activating polypeptide (pacap) and methods for their use |
ES2669190T3 (es) | 2011-06-06 | 2018-05-24 | Phasebio Pharmaceuticals, Inc. | Uso de péptidos intestinales vasoactivos modificados en el tratamiento de la hipertensión |
MY191337A (en) * | 2013-09-17 | 2022-06-16 | Vectus Biosystems Ltd | Compositions for the treatment of hypertension and/or fibrosis |
UA118111C2 (uk) * | 2013-09-17 | 2018-11-26 | Вектус Байосистемз Лімітед | Сполука та композиція для лікування гіпертензії та/або фіброзу |
AU2015255752B2 (en) | 2014-05-08 | 2020-07-23 | Immunoforge Co., Ltd. | Methods and compositions for treating Cystic Fibrosis |
US10688156B2 (en) | 2015-02-09 | 2020-06-23 | Phasebio Pharmaceuticals, Inc. | Methods and compositions for treating muscle disease and disorders |
CN110151973A (zh) * | 2019-04-25 | 2019-08-23 | 上海交通大学医学院附属瑞金医院 | 一种生物活性多肽pacap的应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3880826A (en) * | 1971-09-17 | 1975-04-29 | Sami I Said | Vasoactive intestinal peptide |
US3862927A (en) * | 1973-02-26 | 1975-01-28 | Sami I Said | Process for preparation of vasoactive intestinal peptide |
EP0289587A4 (en) | 1986-11-18 | 1990-12-05 | Senetek Plc | Method for inducing vaginal lubrication |
US4835252A (en) * | 1987-02-26 | 1989-05-30 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Vasoactive intestinal peptide analogs |
US4939224A (en) | 1987-02-26 | 1990-07-03 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Vasoactive intestinal peptide analogs |
JPH0840926A (ja) * | 1994-08-03 | 1996-02-13 | Yakurigaku Chuo Kenkyusho:Kk | 皮膚潰瘍治療薬 |
US6217886B1 (en) * | 1997-07-14 | 2001-04-17 | The Board Of Trustees Of The University Of Illinois | Materials and methods for making improved micelle compositions |
EP1233811A2 (en) * | 1999-11-12 | 2002-08-28 | Leo Rubin | Methods for treating cardiac arrest or pulmonary hypertension and compositions for use therein comprising vasoactive intestinal polypeptide and cardiac device for electrical and chemical regulation and methods of use |
AU2002220720B2 (en) * | 2000-11-28 | 2006-09-14 | Mondobiotech Ag | Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension |
US6911430B2 (en) | 2003-10-01 | 2005-06-28 | Vipogen, Llc | Compositions and methods for treating ileus |
NZ552130A (en) * | 2004-06-11 | 2009-10-30 | Vectus Biosystems Ltd | Compositions and methods for the treatment of cardiovascular disease |
BRPI0620566B8 (pt) * | 2005-12-09 | 2021-05-25 | Vectus Biosystems Ltd | composição, composição para o tratamento profilático ou terapêutico de fibrose miocardial ou uma condição associada, composição para o tratamento profilático ou terapêutico de hipertensão, uso de uma composição, uso de vip ou de um fragmento do mesmo e uso de um vip |
-
2005
- 2005-06-10 NZ NZ552130A patent/NZ552130A/en unknown
- 2005-06-10 CN CN200580026012.0A patent/CN1993137B/zh active Active
- 2005-06-10 KR KR1020167002272A patent/KR101638308B1/ko active IP Right Grant
- 2005-06-10 CA CA2573439A patent/CA2573439C/en active Active
- 2005-06-10 MX MXPA06014462A patent/MXPA06014462A/es active IP Right Grant
- 2005-06-10 AU AU2005251386A patent/AU2005251386B8/en active Active
- 2005-06-10 US US11/629,041 patent/US7951777B2/en active Active
- 2005-06-10 RU RU2007101164/14A patent/RU2387454C2/ru active
- 2005-06-10 EP EP05749305.8A patent/EP1768689B1/en active Active
- 2005-06-10 DK DK05749305.8T patent/DK1768689T3/en active
- 2005-06-10 KR KR1020147011249A patent/KR20140057411A/ko not_active Application Discontinuation
- 2005-06-10 JP JP2007526111A patent/JP4824682B2/ja active Active
- 2005-06-10 ES ES05749305.8T patent/ES2523659T3/es active Active
- 2005-06-10 BR BRPI0511367A patent/BRPI0511367B8/pt active IP Right Grant
- 2005-06-10 WO PCT/AU2005/000835 patent/WO2005120545A1/en active Application Filing
-
2006
- 2006-12-07 IL IL179931A patent/IL179931A/en active IP Right Grant
-
2007
- 2007-01-02 ZA ZA200700070A patent/ZA200700070B/en unknown
- 2007-10-04 HK HK07110799.5A patent/HK1102508A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
RU2007101164A (ru) | 2008-07-20 |
KR20140057411A (ko) | 2014-05-12 |
MXPA06014462A (es) | 2007-05-23 |
US7951777B2 (en) | 2011-05-31 |
BRPI0511367B8 (pt) | 2021-05-25 |
NZ552130A (en) | 2009-10-30 |
AU2005251386B8 (en) | 2010-10-14 |
ZA200700070B (en) | 2008-05-28 |
HK1102508A1 (en) | 2007-11-23 |
CN1993137B (zh) | 2015-04-22 |
EP1768689B1 (en) | 2014-08-20 |
DK1768689T3 (en) | 2014-12-01 |
IL179931A (en) | 2013-08-29 |
AU2005251386A1 (en) | 2005-12-22 |
JP2008501723A (ja) | 2008-01-24 |
CN1993137A (zh) | 2007-07-04 |
AU2005251386B2 (en) | 2010-05-13 |
IL179931A0 (en) | 2007-05-15 |
ES2523659T3 (es) | 2014-11-28 |
KR20160017121A (ko) | 2016-02-15 |
RU2387454C2 (ru) | 2010-04-27 |
WO2005120545A1 (en) | 2005-12-22 |
KR101638308B1 (ko) | 2016-07-08 |
CA2573439C (en) | 2014-12-09 |
JP4824682B2 (ja) | 2011-11-30 |
BRPI0511367B1 (pt) | 2018-05-22 |
EP1768689A4 (en) | 2009-08-12 |
CA2573439A1 (en) | 2005-12-22 |
US20080108573A1 (en) | 2008-05-08 |
EP1768689A1 (en) | 2007-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0511367A (pt) | uso de uma composição,composição, uso de vip e/ou de um fragmento ativo do mesmo | |
BRPI0620566B8 (pt) | composição, composição para o tratamento profilático ou terapêutico de fibrose miocardial ou uma condição associada, composição para o tratamento profilático ou terapêutico de hipertensão, uso de uma composição, uso de vip ou de um fragmento do mesmo e uso de um vip | |
WO2008079270A3 (en) | Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis | |
EA200700684A1 (ru) | Полиаминные композиции | |
MX2010008206A (es) | Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf. | |
BRPI0411319A (pt) | compostos terapeuticamente ativos e sua utilização | |
MY151457A (en) | Topical formulation and uses thereof | |
MX2009002893A (es) | Tratamiento de trastornos hepaticos mediante la administracion de conjugados de la proteina asociada al receptor (rap). | |
TW200716172A (en) | Pharmaceutical compositions for treating lower motor neuron diseases | |
BRPI0512503A (pt) | composição que compreende ácido lático e lactoferrina | |
EA200900662A1 (ru) | Лечение синдрома "сухого глаза" с помощью тестостерона и прогестагена | |
WO2005120557A3 (en) | Inhibition of macrophage-stimulating protein receptor (ron) | |
DE60116256D1 (de) | Zusammensetzungen zur abgabe von cortisolantagonisten | |
UA86400C2 (ru) | Применение эритропоэтина в низком дозировании для пациентов с дисфункцией эндотелиальных клеток-предшественников, сердечно-сосудистым фактором риска и повреждением конечного органа | |
WO2007075439A3 (en) | Compositions and methods for treating obesity and related metabolic disorders | |
WO2008034796A3 (en) | Estratriene derivatives and their uses as 17beta-hydr0xyster0id dehydrogenase inhibitors | |
MY160560A (en) | Compositions and methods for treatment of kidney disorders | |
EA200802128A1 (ru) | Новые нутрицевтические композиции | |
EP2510941A3 (en) | Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist | |
DE602006012115D1 (de) | Behandlung von amyotrophischer lateralsklerose mit pyrimethamin und analoga | |
EP2502996A3 (en) | Anti-FGF23 antibody and pharmaceutical composition comprising the same | |
WO2007123848A3 (en) | Therapeutic compositions containing modified class i slrp proteins | |
WO2004043456A8 (en) | Cholesterol absorption inhibitors for the treatment of demyelination | |
WO2006135493A3 (en) | A composition for wound healing and use thereof | |
CY1119819T1 (el) | Παραθυρεοειδης ορμονη (ρτη) για χρηση στην θεραπεια ισχαιμιας |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] | ||
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/06/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |